ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) Form 6-K — Jun 1, 2026
Ascentage Pharma Group International presented three rapid oral presentations at the ASCO 2026 Annual Meeting, highlighting positive clinical data for its key pipeline assets. The company reported that its MDM2-p53 inhibitor alrizomadlin (APG-115) showed an objective response rate of 23.5% and a disease control rate of 70.6% in pediatric patients with relapsed or metastatic solid tumors, including complete responses in rhabdomyosarcoma and Ewing sarcoma.
Key figures
- Alrizomadlin dcr
- 70.6%
- Alrizomadlin orr
- 23.5%
- Olverembatinib cr or cri
- 91%
- Olverembatinib mmr cycle24
- 60.9%
- Olverembatinib ccyr cycle24
- 91.3%
- Olverembatinib mrd negativity
- 80%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.